Drug Trial Radar · NCT03108027
Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma
Last checked: Nov 19, 2026Latest source record: Jan 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Jun 26, 2017
Primary completion
Feb 24, 2018
Study completion Feb 24, 2018
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 11, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a randomized, placebo-controlled, double-blind, six-sequence, three-period cross-over study in asthma patients. The study consisted of a 14-day screening period, followed by a 14-day run-in period, and a treatment epoch which consists of three treatment periods, with a minimum duration of 14 days each followed (for the 2 first treatment periods) by a wash-out period. The duration of each treatment period may be extended up to a duration of 18 days if needed for operational reasons. The third treatment period was followed by a Study Completion evaluation at 1-7 days following the last dose. The treatment periods were separated by wash-out periods of 14 to 21 days duration.
Conditions
- Asthma
Interventions
Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)Drug
Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)
Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)Drug
QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)
Treatment C: Placebo (morning dose) and placebo (evening dose)Drug
Placebo (morning dose) and placebo (evening dose)
Primary outcomes
What the sponsor says the trial is designed to measure.
- FEV1 Standardized Area Under the Curve (AUC 0-24h) After Last Evening Dose of 14-day Treatment PeriodTime frame: At the end of each treatment period day 14 pre-dose to 24 hours post-dose.
Locations
7 sites in 3 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Frankfurt Am Main Hessen, Germany
Novartis Investigative Site
Großhansdorf, Germany
Novartis Investigative Site
Hanover, Germany
Novartis Investigative Site
Wiesbaden, Germany
Novartis Investigative Site
Groningen, GZ, Netherlands
Novartis Investigative Site
Machester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.